Ursula Rauch-Krohnert

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Uromodulin as a genetically anchored biomarker stratifies time to valve intervention in aortic regurgitation.

Uromodulin as a genetically anchored biomarker stratifies time to valve intervention in aortic regurgitation.

Journal: Frontiers in cardiovascular medicine

Published: March 26, 2026

Adenine Nucleotide Translocase: From Nucleotide Carrier to a Modulator of Mitochondrial Bioenergetics, Quality Control, and Cellular Communication.

Adenine Nucleotide Translocase: From Nucleotide Carrier to a Modulator of Mitochondrial Bioenergetics, Quality Control, and Cellular Communication.

Journal: Cells

Published: February 26, 2026

Significance of FXa and its receptor PAR2 for the growth of colon cancer cells in vitro and in vivo.

Significance of FXa and its receptor PAR2 for the growth of colon cancer cells in vitro and in vivo.

Journal: Frontiers in oncology

Published: May 28, 2025

Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial.

Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial.

Journal: JAMA

Published: March 30, 2025

Dual pathway inhibition in patients with peripheral artery disease in Germany.

Dual pathway inhibition in patients with peripheral artery disease in Germany.

Journal: VASA. Zeitschrift fur Gefasskrankheiten

Published: January 10, 2025

Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR-HF2-DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trials.

Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR-HF2-DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trials.

Journal: European journal of heart failure

Published: December 22, 2024

Lipid-Lowering Efficiency and Safety of Alirocumab 300 mg Using a 2-mL Autoinjector Device in Real-World Practice: The MARS Study.

Lipid-Lowering Efficiency and Safety of Alirocumab 300 mg Using a 2-mL Autoinjector Device in Real-World Practice: The MARS Study.

Journal: Drugs - real world outcomes

Published: November 27, 2024

Dual pathway inhibition in patients with coronary artery disease (CAD) in clinical practice in Germany: results from the German CAD subgroup of the XATOA Registry.

Dual pathway inhibition in patients with coronary artery disease (CAD) in clinical practice in Germany: results from the German CAD subgroup of the XATOA Registry.

Journal: Clinical research in cardiology : official journal of the German Cardiac Society

Published: July 14, 2024

Characteristics of Patients With Asymptomatic Atrial Fibrillation and Ischemic Stroke-Insights From the GLORIA-AF Registry (Phase 2).

Characteristics of Patients With Asymptomatic Atrial Fibrillation and Ischemic Stroke-Insights From the GLORIA-AF Registry (Phase 2).

Journal: Pacing and clinical electrophysiology : PACE

Published: February 17, 2024

Characterization of Biomarkers of Thrombo-Inflammation in Patients with First-Diagnosed Atrial Fibrillation.

Characterization of Biomarkers of Thrombo-Inflammation in Patients with First-Diagnosed Atrial Fibrillation.

Journal: International journal of molecular sciences

Published: January 26, 2024

Protease-Activated Receptor-1 IgG Autoantibodies in Patients with COVID-19.

Protease-Activated Receptor-1 IgG Autoantibodies in Patients with COVID-19.

Journal: Thrombosis and haemostasis

Published: November 06, 2023

The Role of NETosis and Complement Activation in COVID-19-Associated Coagulopathies.

The Role of NETosis and Complement Activation in COVID-19-Associated Coagulopathies.

Journal: Biomedicines

Published: April 05, 2023

Showing 1-12 of 47

Last Updated: 09/26/2026